Pivotal Trials in mHSPC

Opinion
Video

In this segment, Dr. Shore will review the findings of several pivotal Phase 3 trials evaluating the efficacy of various treatments in metastatic hormone-sensitive prostate cancer patients, including the MAGNITUDE, PROpel, and TALAPRO-2 trials, among others.

Recent Videos
4 KOLs are featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
3 KOLs are featured in this series.
Related Content
Radiopharmaceuticals and Radiation Therapy for Prostate Cancer Treatment

Radiopharmaceuticals and Radiation Therapy for Prostate Cancer Treatment

Jordyn Sava
October 1st 2024
Article

Savita Dandapani, MD, PhD, discussed combining radium-223 and SBRT for metastatic castration-sensitive prostate cancer.

Read More

Transforming Prostate Cancer Care Through Personalized Medicine

Transforming Prostate Cancer Care Through Personalized Medicine

Jordyn Sava;Adam Weiner, MD
July 1st 2024
Podcast

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

Listen

Precision Medicine for Prostate Cancer: The Role of Radiopharmaceuticals

Precision Medicine for Prostate Cancer: The Role of Radiopharmaceuticals

Sabrina Serani
September 27th 2024
Article

For Prostate Cancer Awareness Month, Jeffrey Y.C. Wong, MD, discussed the evolving field of prostate cancer treatment and how it continues to improve.

Read More

A Deep Dive Into the Evolving Landscape of Prostate Cancer

A Deep Dive Into the Evolving Landscape of Prostate Cancer

Jordyn Sava;Badrinath Konety, MD
January 15th 2024
Podcast

In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.

Listen

Darolutamide Plus ADT Shows Efficacy and Safety Vs ADT Alone in mHSPC

Darolutamide Plus ADT Shows Efficacy and Safety Vs ADT Alone in mHSPC

Jonah Feldman
September 16th 2024
Article

The ARANOTE trial confirmed radiographical PFS benefit to adding darolutamide to androgen deprivation therapy without docetaxel in the metastatic hormone-sensitive prostate cancer setting.

Read More

Sequencing Matters: Giving Radium-223 Prior to Docetaxel Leads to Improved HRQOL, Tolerability in mCRPC

Sequencing Matters: Giving Radium-223 Prior to Docetaxel Leads to Improved HRQOL, Tolerability in mCRPC

Tony Berberabe, MPH
September 16th 2024
Article

The RAPSON trial found that receiving radium-223 prior to docetaxel in patients with metastatic castration-resistant prostate cancer improved quality of life and tolerability compared to the reverse sequence, without affecting progression-free survival or overall survival.

Read More